Navigation Links
ShangPharma Subsidiary and Jiangsu Hengrui Medicine Partner in Therapeutic Antibody Research and Development
Date:9/15/2011

SHANGHAI, Sept. 15, 2011 /PRNewswire-Asia/ -- ShangPharma Corporation (NYSE: SHP) ("ShangPharma" or the "Company"), a leading China-based pharmaceutical and biotechnology research and development outsourcing company, and Jiangsu Hengrui Medicine Co., Ltd. ("Hengrui"), a leading Chinese pharmaceutical company, today announced that Shanghai ChemPartner ("ChemPartner"), a wholly owned subsidiary of ShangPharma, and Hengrui have entered into a strategic partnership for the development of novel therapeutic monoclonal antibodies ("mAbs").

Through the partnership, ChemPartner and Hengrui will initially collaborate on the development of novel therapeutic mAbs in a major therapeutic area. ChemPartner will head pre-clinical research activities, including target protein preparation and assay system establishment, generation and optimization of lead antibodies, as well as pharmacokinetic and preformulation studies, while Hengrui will lead drug development for the mAb. Following the project's completion, Hengrui will retain the intellectual property rights of the mAb and any patents related to the mAb's development. The first program will have several preclinical and development milestone payments, as well as a timeline-based incentive payment.

Mr. Michael Xin Hui, chairman and chief executive officer of ShangPharma, commented, "Hengrui is the first major domestic pharmaceutical company to form such an antibody partnership with ChemPartner, and the program is the first of its kind in China. The indication and market potential for the first mAb is very broad. We are proud to be working with Hengrui, one of the major domestic pharmaceutical companies. We expect our collaborative work will lead to further domestic and multinational partnerships in biologics development, and pave the way for innovation and growth in China's own biotechnology industry."

Dr. Lianshan Zhang, Hengrui's President of Global R&D, added, "Hengrui, as a domestic leader in innovative medicines, recognizes the importance of external discovery capability, especially in the area of biotherapeutics. We are pleased to be working with one of the leading CRO companies in China. Hengrui has chosen to partner with ShangPharma and its ChemPartner subsidiary for their exceptional capabilities and platform in biologics R&D, and we will work together toward a successful partnership."

About JiangsuHengrui Medicine Co., Ltd.Jiangsu Hengrui Medicine Co., Ltd., established in 1970, is a fully integrated pharmaceutical company in China, with net sales of about US$550 million in 2010. The company has been experiencing organic growth at an annual rate of 25% in the past few years. It is recognized as the top innovative home-grown drug company, with over a dozen of new molecular entities in clinical trials and dozens more under pre-clinical development. Hengrui's products and R&D span over multiple therapeutic areas, such as oncology, cardiovascular and metabolic diseases, CNS, inflammation, hematology and anesthesiology. For more information, please visit http://www.hrs.com.cn/.

About Shanghai ChemPartnerFounded in 2003, Shanghai ChemPartner (ChemPartner) is one of the leading contract research organizations providing medicinal chemistry, discovery biology, pharmacology, DMPK, toxicology, process R&D, analytical development, formulation and contract manufacturing services to over 120 pharmaceutical and biotech companies in the world. ChemPartner currently has a team of over 1,000 scientists including more than 100 senior scientific leaders with extensive industry experiences gained from leading global pharmaceutical and biotech companies. Headquartered in China, ChemPartner has overseas business development operations in Boston, USA and Copenhagen, Denmark. For more information, please visit www.chempartner.cn.

About ShangPharma Corporation  ShangPharma Corporation is a leading China-based contract research organization providing high-quality and cost-effective services for the pharmaceutical and biotechnology industry. It offers a broad range of high-quality, integrated services across the drug discovery and development process to help international and Chinese pharmaceutical and biotechnology companies discover and develop novel drug candidates efficiently. ShangPharma's services consist of discovery chemistry, discovery biology and preclinical development, pharmaceutical development and biologics services. For more information, please visit www.shangpharma.com. For further information, please contact:ShangPharma CorporationIn Shanghai, ChinaMs. Lan XieVP of Finance and Investor RelationsEmail: IR@shangpharma.com ChristensenIn New York:Kimberly MinarovichTel: +1 917-533-3268Email: kminarovich@christensenir.com In Hong Kong:Tip Fleming Tel: +852-9212-0684Email: tfleming@christensenir.com
'/>"/>

SOURCE ShangPharma Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. ShangPharma Announces Second Quarter 2011 Results
2. ShangPharma Corporation Named a Top Ten Chinese Outsourcing Enterprise
3. ShangPharma Announces First Quarter 2011 Results
4. ShangPharma Corp. to Announce Fourth Quarter and Full Year 2010 Financial Results on March 15, 2011
5. ImaginAb, Inc. Announces Formation of Singapore Subsidiary, ImaginAb Molecular Imaging Pte Ltd.
6. Infrared Systems Internationals Subsidiary, AquaLiv Inc., Explains Its Revolutionary Technology in Laymans Terms
7. Infrared Systems Internationals Subsidiary, AquaLiv, Inc., Strives to Be a Game Changer in Fight Against HIV/AIDS
8. AquaStar Holdings, Inc. Subsidiary Appoints Former Beckman Coulter Executive as Vice President of Operations
9. New England Biolabs Opens New Subsidiary Office in France
10. Beijing Chaoyang District Court Grants Investigation Letters Against Inverness Medical Beijing, A Subsidiary of Alere Inc.
11. China Cord Blood Corporation Forms Zhejiang Subsidiary
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering ... retention in this eBook by providing practical tips, tools, and strategies for clinical ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. ... test has received AOAC Research Institute approval 061601. , “This is another AOAC-RI ... stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate ...
Breaking Biology Technology:
(Date:5/12/2016)... 2016 WearablesResearch.com , a brand of ... results from the Q1 wave of its quarterly wearables ... consumers, receptivity to a program where they would receive ... insurance company. "We were surprised to see ... Michael LaColla , CEO of Troubadour Research, "primarily because ...
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
(Date:4/15/2016)... CHICAGO , April 15, 2016  A ... companies make more accurate underwriting decisions in a ... offering timely, competitively priced and high-value life insurance ... health screenings. With Force Diagnostics, rapid ... and lifestyle data readings (blood pressure, weight, pulse, ...
Breaking Biology News(10 mins):